Capricor Therapeutics Inc. - Pangali EV/EBITDA CAPR

Capricor Therapeutics develops cellular therapies to combat rare genetic pathologies, leveraging collaborations with scientific centers and pharmaceutical behemoths. This EV/EBITDA chart, with a value of 0.00, reflects price action driven by reliance on Asian raw material imports and logistical risks. Meanwhile, a narrow focus on Duchenne muscular dystrophy therapy creates a high dependency of the share price on the outcome of final tests.

The ratio is calculated as the total enterprise value (market capitalization plus net debt) divided by earnings before interest, taxes, depreciation, and amortization. This metric determines the payback period of assets, excluding the impact of the tax regime and debt load. For Capricor Therapeutics (CAPR), with its capital-intensive neurological research, this is a critical marker for the efficiency of managing billion-dollar investments. Analyzing the EV/EBITDA chart allows for the identification of points where the company's capacities are undervalued.